Navigation Links
Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
Date:11/7/2007

SAN DIEGO, CA, Nov. 7 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the third quarter ended September 30, 2007. All amounts, unless specified otherwise, are in Canadian dollars.

Nventa reported a net loss of $3.1 million or $0.01 per share, for the three months ended September 30, 2007, compared to a net loss of $2.3 million, or $0.03 per share, for the same period in 2006. For the nine months ended September 30, 2007, the Company reported a net loss of $10.1 million, or $0.05 per share, compared to a net loss of $8.0 million, or $0.10 per share, for the same period in 2006. The Company's net loss for the nine months ended September 30, 2007 included approximately $0.8 million in one-time corporate restructuring expenses.

The Company had cash and cash equivalents of $14.3 million as of September 30, 2007.

RECENT NVENTA HIGHLIGHTS

- Initiated and dosed the first cohort of patients in the Company's

HspE7 Phase 1 clinical trial in cervical intraepithelial neoplasia;

- Raised $8.6 million in additional capital through a Short Form

Prospectus Offering;

- Strengthened management team with addition of David Duncan Jr.,

Vice President of Finance;

- Assembled distinguished group of international experts for Clinical

and Scientific Advisory Board;

- Presented additional data at the 24th International Papillomavirus

Conference and Clinical Workshop that demonstrate that new HspE7

promotes more potent immune responses;

- Granted new U.S. patent for Nventa's CoVal(TM) fusions covering their

use in patients with human papillomavirus (HPV)-related diseases;

- Published data in Clinical and Vaccine Immunology demonstrating

ability of new HspE7 to elicit long-lasting tumor protection in vivo,

suggesting that HspE7 may have utility in (HPV)-infected
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
9. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
10. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
11. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... UCLA ... months ago. Conventional treatment and therapy were not working so Zach decided to ... Dr. McKenna treated Zack with precisely guided injections of bone marrow aspirate concentrate ...
(Date:9/3/2015)... , Sept. 3, 2015 /PRNewswire/ - bioLytical Laboratories ... to announce its study " Sensitivity of a rapid ... is enhanced by its affinity for HIV gp41 IgM ... Clinical Virology.  This study highlights INSTI,s ability to detect ... their findings at the 8 th annual International ...
(Date:9/3/2015)... ... ... Park Systems announced that they will host a free webinar ... webinar will focus on the methods and materials for additive manufacturing – beyond their ... broad term that encompasses “addition or fusion” of materials to create an object. This ...
(Date:9/2/2015)... , Sept. 2, 2015 Axovant Sciences Ltd. ... treatment of dementia, today announced upcoming presentations at three investor ... at the Baird 2015 Healthcare Conference in New ... , Thursday, September 10 at 2:00 PM at the BioCentury ... the Millennium Broadway Hotel & Conference Center , Thursday, ...
Breaking Biology Technology:UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 2UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 3bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 4Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3
... Ill. and Exton, Pa., Oct. 12 ... virtual reality (VR) based medical,simulation systems and ... clinical skills training and evaluation software solutions, ... in,Washington D.C., an OEM partnership that enables ...
... CorMatrix Cardiovascular, Inc., an,Atlanta-based company dedicated ... biomaterial devices that harness the body,s,innate ability ... Robert G. Matheny, M.D., Chief Scientific Officer, ... ECM Technology(TM) at the annual,Transcatheter Cardiovascular Therapeutics ...
... Call to be Held on October 16th, SAN ... that the company will release its fourth quarter and,year ... and will,subsequently host a conference call on Thursday, October ... will consist of prepared,remarks from management and will be ...
Cached Biology Technology:Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership 2Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership 3CorMatrix Cardiovascular to Present Data on Its Next Generation ECM Technology(TM) at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C. 2PURE Bioscience to Announce Fourth Quarter and Fiscal 2008 Results 2
(Date:8/28/2015)... -- According to a new market research ... (Pen & Paper Based, Hosted, Biometrics), Service, Application (Clinical ... Vertical and Region - Global Forecast to 2020", published ... from USD 2.4 Billion in 2015 to USD 7.5 ... (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/24/2015)... , August 24, 2015 The consulting ... ,s largest biometrics manufacturer DERMALOG and its customized solutions and ... African Biometrics Company of the Year Award". DERMALOG is particularly ... .   -Cross reference: Picture is available ... - On Thursday evening, in South ...
(Date:8/20/2015)... 2015   Sensory, Inc ., a Silicon ... experience and security of consumer electronics through state-of-the-art ... its TrulySecure™ is the first multimodal ... FIDO Certified™. The FIDO (Fast Identification ... FIDO UAF (Universal Authentication Framework) 1.0 specifications, which ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... to findings by UT Southwestern Medical Center researchers, individuals ... clots, or thrombosis, might someday receive therapy to prevent ... in a future issue of The Journal of ... underlying antiphospholipid syndrome (APS). "Patients with APS ...
... have recorded stunning images of the UK,s winter landscape ... have been observing the icy blast in the UK ... scientists have used two instruments, MERIS and AATSR, which ... observations on November 29th and December 1st. ...
... alteration of a single gene could cause some male ... improve diagnosis and clinical management of patients with disorders ... testis or ovary does not develop properly in the ... An international team including researchers from the ...
Cached Biology News:UT Southwestern researchers uncover culprits in life-threatening clotting disorder 2Snow from space: University of Leicester releases satellite images of snow-bound UK 2
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
... Compatible with AutoGen AutoGenesys, BioRobotics BioPick, BioGrid, ... colony picking systems This CLS number is ... match Cornings product number. If showing no ... Sigma-Aldrich number (D9314) or contact customer service ...
Biology Products: